TRADES
Latest Trades
66
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 8 Sep 2021 Sell MCRB SERES THERAPEUTICS INC 97 0.0000
ARKG 7 Sep 2021 Sell MCRB SERES THERAPEUTICS INC 900 0.0000
ARKK 7 Sep 2021 Sell MCRB SERES THERAPEUTICS INC 260 0.0000
ARKG 3 Sep 2021 Sell MCRB SERES THERAPEUTICS INC 19,400 0.0000
ARKK 3 Sep 2021 Sell MCRB SERES THERAPEUTICS INC 11,856 0.0000
ARKG 2 Sep 2021 Sell MCRB SERES THERAPEUTICS INC 383,560 0.0300
ARKK 2 Sep 2021 Sell MCRB SERES THERAPEUTICS INC 50,000 0.0000
ARKG 1 Sep 2021 Sell MCRB SERES THERAPEUTICS INC 682,519 0.0517
ARKK 1 Sep 2021 Sell MCRB SERES THERAPEUTICS INC 51,957 0.0015
ARKK 31 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 576,762 0.0162
ARKK 30 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 846,468 0.0239
ARKG 27 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 707,095 0.0539
ARKK 27 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 575,000 0.0166
ARKG 26 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 400 0.0000
ARKK 24 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 45,359 0.0013
ARKK 23 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 184,949 0.0056
ARKK 19 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 10,974 0.0003
ARKK 18 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 3,968 0.0001
ARKK 17 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 29,880 0.0009
ARKK 16 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 370,736 0.0108
ARKK 13 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 14,751 0.0004
ARKK 12 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 269,026 0.0081
ARKK 11 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 187,418 0.0057
ARKK 10 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 100 0.0000
ARKK 9 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 51,484 0.0016
ARKK 6 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 13,359 0.0004
ARKK 5 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 246,378 0.0075
ARKG 4 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 392,172 0.0319
ARKG 3 Aug 2021 Sell MCRB SERES THERAPEUTICS INC 195,680 0.0159
ARKK 30 Jul 2021 Sell MCRB SERES THERAPEUTICS INC 487,221 0.0153
ARKK 29 Jul 2021 Sell MCRB SERES THERAPEUTICS INC 938,561 0.0298
ARKK 19 Jan 2021 Sell MCRB SERES THERAPEUTICS INC 76,444 0.0100
ARKK 15 Jan 2021 Sell MCRB SERES THERAPEUTICS INC 3,973 0.0005
ARKK 14 Jan 2021 Sell MCRB SERES THERAPEUTICS INC 38,693 0.0000
ARKK 13 Jan 2021 Sell MCRB SERES THERAPEUTICS INC 33,987 0.0000
ARKK 12 Jan 2021 Sell MCRB SERES THERAPEUTICS INC 75,715 0.0094
ARKK 11 Jan 2021 Sell MCRB SERES THERAPEUTICS INC 2,260 0.0003
ARKK 8 Jan 2021 Sell MCRB SERES THERAPEUTICS INC 72,313 0.0096
ARKK 7 Jan 2021 Sell MCRB SERES THERAPEUTICS INC 91,363 0.0127
ARKK 17 Nov 2020 Sell MCRB SERES THERAPEUTICS INC 54,000 0.0175
ARKK 16 Nov 2020 Sell MCRB SERES THERAPEUTICS INC 10,492 0.0033
ARKK 13 Nov 2020 Sell MCRB SERES THERAPEUTICS INC 16,582 0.0053
ARKK 12 Nov 2020 Sell MCRB SERES THERAPEUTICS INC 66,955 0.0212
ARKK 11 Nov 2020 Sell MCRB SERES THERAPEUTICS INC 74,929 0.0235
ARKK 10 Nov 2020 Sell MCRB SERES THERAPEUTICS INC 12,822 0.0041
ARKK 5 Nov 2020 Sell MCRB SERES THERAPEUTICS INC 58,464 0.0190
ARKK 4 Nov 2020 Sell MCRB SERES THERAPEUTICS INC 47,000 0.0148
ARKK 3 Nov 2020 Sell MCRB SERES THERAPEUTICS INC 19,476 0.0060
ARKK 29 Oct 2020 Sell MCRB SERES THERAPEUTICS INC 2,877 0.0009
ARKK 28 Oct 2020 Sell MCRB SERES THERAPEUTICS INC 8,933 0.0026
ARKK 27 Oct 2020 Sell MCRB SERES THERAPEUTICS INC 24,580 0.0071
ARKK 20 Oct 2020 Sell MCRB SERES THERAPEUTICS INC 6,930 0.0021
ARKG 7 Oct 2020 Sell MCRB SERES THERAPEUTICS INC 52,600 0.0596
ARKG 6 Oct 2020 Sell MCRB SERES THERAPEUTICS INC 1,906 0.0023
ARKG 5 Oct 2020 Sell MCRB SERES THERAPEUTICS INC 64,700 0.0766
ARKK 29 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 135,788 0.0432
ARKK 28 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 72,906 0.0221
ARKK 25 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 17,800 0.0053
ARKK 24 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 81,146 0.0244
ARKK 23 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 21,597 0.0067
ARKK 22 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 90,571 0.0279
ARKG 17 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 6,549 0.0082
ARKG 16 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 57,100 0.0730
ARKG 15 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 80,076 0.1043
ARKK 10 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 131,632 0.0419
ARKK 9 Sep 2020 Sell MCRB SERES THERAPEUTICS INC 144,510 0.0448
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.